使用互补统计方法评估长期治疗获益:对III期Keynote-045与Checkmate-214免疫检查点抑制剂试验的计算机模拟分析
该研究基于Keynote-045(尿路上皮癌)和Checkmate-214(晚期肾细胞癌)的个体患者数据,比较里程碑生存与含治愈的灵活参数生存模型(FPCM)评估免疫检查点抑制剂(ICI)的长期获益(LTB)。结果显示两试验均存在非比例风险;Keynote-045长期分析中FPCM识别出PFS的时间依赖效应,而Cox模型未发现统计学差异(HR 0.90,95%CI 0.75-1.08)。作者指出晚期肾细胞癌初治患者可能被纳武利尤单抗联合伊匹木单抗功能性治愈,而二线尿路上皮癌则不然,但未来工作需确定性验证该结论。
要点
- Keynote-045长期分析中FPCM识别PFS时间依赖效应,Cox模型未发现统计学差异(HR 0.90,95%CI 0.75-1.08)。
- 里程碑生存与FPCM均识别出LTB比例的改善,与基于较短随访的再分析结果一致。
- Checkmate-214中Cox模型和FPCM均识别出PFS改善,里程碑生存和FPCM显示LTB比例改善。
核心结论
- 尽管基于常规Kaplan-Meier或Cox模型分析,ICI在PFS方面显示向LTB的显著转移,但本研究方法为新疗法的获益-风险比提供了替代评估并促进向患者传达风险。
- 接受ICI治疗的肾脏患者可被告知他们可能被治愈,但未来工作需确定性验证该结论。
- 作者认为晚期肾细胞癌初治患者被纳武利尤单抗联合伊匹木单抗功能性治愈,而二线尿路上皮癌则不然。
研究设计与样本
- 基于Keynote-045(尿路上皮癌)和Checkmate-214(晚期肾细胞癌)初始及随访分析的个体患者数据,重建PFS。
- 每项试验使用Cox比例风险回归和两种互补方法(里程碑生存和FPCM)重新分析以估计治疗对LTB的影响。
主要发现
- 每项试验均存在非比例风险的证据。
- Keynote-045长期分析中,FPCM识别出PFS的时间依赖效应,但Cox模型未发现PFS统计学差异(HR 0.90,95%CI 0.75-1.08)。
- 里程碑生存和FPCM识别出LTB比例的改善,与基于较短随访的Keynote-045再分析结果一致,尽管LTB比例未保留。
- Checkmate-214中PFS的增加由Cox模型和FPCM均识别出,里程碑生存和FPCM显示实验治疗依赖的LTB比例改善。
- FPCM估计的LTB比例与较短随访期再分析结果一致。
临床怎么用
- 作者认为,接受ICI治疗的肾脏患者可被告知他们可能被治愈,但未来工作需确定性验证该结论。
- 作者认为,晚期肾细胞癌初治患者被纳武利尤单抗联合伊匹木单抗功能性治愈,而二线尿路上皮癌则不然。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Keynote-045 trial illustrates that the long-term benefit (LTB) of treatment does not always translate to improved progression-free survival (PFS). Milestone survival and flexible parametric survival model with cure (FPCM) have been proposed as complementary statistical approaches to more comprehensively evaluate LTBs of treatments. OBJECTIVE: The current study compares milestone survival and FPCM analyses to evaluate treatment effects of immune checkpoint inhibitor (ICI) phase III trials. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data, from initial and follow-up analyses of Keynote-045 (urothelial cancer) and Checkmate-214 (advanced renal cell carcinoma), were reconstructed for PFS. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Each trial was reanalyzed using the Cox proportional hazard regression and two complementary methods (milestone survival and FPCM) to estimate treatment impact on the LTB. RESULTS AND LIMITATIONS: For each trial, there was evidence of nonproportional hazards. For the long-term analysis of the Keynote-045 trial, FPCM identified a time-dependent effect on PFS, but the Cox model found no statistical difference in PFS (hazard ratio, 0.90; 95% confidence interval, 0.75-1.08). Milestone survival and FPCM identified improvements in the LTB fractions. This was consistent with the results from the reanalysis of Keynote-045, based on the shorter follow-up, although the LTB fraction was not retained. The increase in PFS in Checkmate-214 was identified by both Cox model and FPCM. Experimental treatment-dependent improvement in the LTB fraction was demonstrated using milestone survival and FPCM. The LTB fraction estimated with FPCM was consistent with the results from the reanalysis of the shorter follow-up period. CONCLUSIONS: Although ICIs show substantial shifts toward LTBs in terms of PFS, based on a conventional Kaplan-Meier or Cox model analysis, our approach provides an alternative assessment of benefit-risk ratios for new therapeutics and facilitates communicating risk to patients. Kidney patients treated with ICIs can be counseled that they are potentially cured, but future work will need to definitively validate this conclusion. PATIENT SUMMARY: Although immune checkpoint inhibitor treatments show substantial shifts toward long-term benefits in terms of progression-free survival, a more rigorous attempt to quantify this shift, rather than simply using a Kaplan-Meier estimate or comparing progression-free survival curves using the classic Cox model, is warranted. Our results suggest that advanced renal cell carcinoma patients who had not received a previous treatment are functionally cured by nivolumab and ipilimumab, which is not the case for second-line urothelial carcinoma.
引用
- Cavillon A, Pouessel D, Houédé N, et al. Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials. Eur Urol. 2023. PMID: 36849297. doi:10.1016/j.eururo.2023.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。